报价延迟最少15分钟:2026/03/03 21:32 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
131.14 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
4.67/7.70
|
|
企业价值
13.70B
|
| 资产负债 |
|
每股账面净值
32.41
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
2.86B
|
|
每股收益
17.77
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products. |
